Immune Therapeutics (OTCMKTS:IMUND) Shares Up 2.9%

Immune Therapeutics, Inc. (OTCMKTS:IMUNDGet Rating)’s share price shot up 2.9% on Monday . The stock traded as high as $1.76 and last traded at $1.75. 600 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 1,650 shares. The stock had previously closed at $1.70.

The company has a 50 day moving average of $1.90 and a two-hundred day moving average of $2.15.

Immune Therapeutics Company Profile (OTCMKTS:IMUND)

Immune Therapeutics, Inc, a late development-stage biopharmaceutical company, focuses on the development, commercialization, and licensing of prescription medications for humans, animals, and pets worldwide. It develops low dose naltrexone and methionine encephalin therapies for human immunodeficiency virus (HIV) infections, autoimmune diseases, immune disorders, or cancer.

Further Reading

Want More Great Investing Ideas?

Receive News & Ratings for Immune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.